Traws Pharma, Inc. (TRAW)
TRAW Stock Price Chart
Explore Traws Pharma, Inc. interactive price chart. Choose custom timeframes to analyze TRAW price movements and trends.
TRAW Company Profile
Discover essential business fundamentals and corporate details for Traws Pharma, Inc. (TRAW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jul 2013
Employees
6.00
Website
https://www.trawspharma.comCEO
Iain D. Dukes
Description
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
TRAW Financial Timeline
Browse a chronological timeline of Traws Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.34.
Earnings released on 15 May 2026
EPS came in at -$0.53 surpassing the estimated -$0.92 by +42.39%.
Earnings released on 15 Apr 2026
EPS came in at -$0.71 surpassing the estimated -$1.22 by +41.98%.
Earnings released on 13 Nov 2025
EPS came in at -$0.34 surpassing the estimated -$9.16 by +96.29%.
Earnings released on 14 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$8.75 by +98.74%, while revenue for the quarter reached $2.73m , beating expectations by +4.46k%.
Earnings released on 15 May 2025
EPS came in at $2.09 surpassing the estimated -$8.04 by +126.00%, while revenue for the quarter reached $57.00k , missing expectations by -5.00%.
Earnings released on 15 May 2025
EPS came in at $2.09 surpassing the estimated -$9.55 by +121.88%, while revenue for the quarter reached $56.00k , missing expectations by -6.67%.
Earnings released on 14 Nov 2024
EPS came in at -$8.81 falling short of the estimated -$6.25 by -40.96%, while revenue for the quarter reached $57.00k , missing expectations by -5.00%.
Earnings released on 14 Nov 2024
EPS came in at -$8.81 falling short of the estimated -$6.25 by -40.96%, while revenue for the quarter reached $57.00k , missing expectations by -5.00%.
Stock split effective on 23 Sept 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 May 2024
EPS came in at -$6.00 falling short of the estimated -$5.88 by -2.13%, while revenue for the quarter reached $56.00k , missing expectations by -6.67%.
Earnings released on 15 May 2024
EPS came in at -$6.00 matching the estimated -$6.00, while revenue for the quarter reached $56.00k , missing expectations by -14.29%.
Earnings released on 14 Nov 2023
EPS came in at -$5.75 surpassing the estimated -$7.25 by +20.69%, while revenue for the quarter reached $57.00k , missing expectations by -17.69%.
Earnings released on 15 May 2023
EPS came in at -$7.00 surpassing the estimated -$7.44 by +5.88%, while revenue for the quarter reached $56.00k , missing expectations by -29.11%.
Earnings released on 14 Nov 2022
EPS came in at -$6.50 falling short of the estimated -$5.31 by -22.35%, while revenue for the quarter reached $57.00k , missing expectations by -22.62%.
Earnings released on 11 May 2022
EPS came in at -$0.20 falling short of the estimated -$0.19 by -6.67%, while revenue for the quarter reached $56.00k , missing expectations by -29.11%.
TRAW Stock Performance
Access detailed TRAW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
